Cibisatamab (CD3E/CEACAM5) Antibody, Monoclonal | 10-880

Cibisatamab (CD3E/CEACAM5) Antibody, Monoclonal | 10-880 | Gentaur UK, US & Europe Distribution

Host: N/A

Reactivity: N/A

Homology: N/A

Immunogen: Humanized / CD3E/CEACAM5 [Homo sapiens]

Research Area: Drug Analogues

Tested Application: N/A

Application: N/A

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: >95%

Clonality: Monoclonal

Clone: N/A

Isotype: IgG1-kappa/lambda with domain crossover

Conjugate: Unconjugated

Physical State: N/A

Buffer: PBS buffer pH7.5

Concentration: N/A

Storage Condition: Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚C for 1-2 weeks. Store at -20 ˚C for 12 months. Store at -80 ˚C for long term storage.

Alternate Name: CEA TCB, RG-7802, RO-6958688

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: Cibisatamab (CEA-TCB) is T cell bispecific antibody that binds to carcinoembryonic antigen (CEA) on cancer cells and CD3 on T cells. Cibisatamab has one single CD3 epsilon chain binding site and two CEA binding sites on T cells (which regulates the binding affinity to cancer cells with high expression of CEA on the cell surface) . This avoids targeting healthy epithelial cells with low CEA expression levels. T cell activation is triggered by binding to CEA on the surface of cancer cells and CD3 on T cells, cytokine secretion and release of cytotoxic particles.